TOP HEADLINES

Featured Story

  • Pfizer continues to explore virtual trials with 23andMe pact

    Pfizer and 23andMe have teamed up to identify genetic factors linked to inflammatory bowel disease. And with 23andMe trumpeting the fact that people can participate without leaving their homes, the study represents a continuation of Pfizer's interest in virtual trials.

PatientPowered.us wins PCORI clinical trial matchmaking app competition

In the years since the Affordable Care Act birthed the Patient-Centered Outcomes Research Institute, the group has committed resources to lowering barriers between those who participate in and run clinical trials. The latest element of this initiative has now come to fruition, with PCORI naming PatientPowered.us as the winner of its Matchmaking App Challenge.

The FDA commits $16M to track prescription drug use

The FDA has set aside $16 million for tracking which drugs are used, in what combinations and for how long, Regulatory Focus reports.

NIH backs database-driven approach to neuromuscular research

The National Institutes of Health (NIH) has awarded a clutch of big-name academic centers funding to create a database for studying motor neuron disorders. By embarking on a large-scale data generation drive and analyzing the resulting information, the collaborators hope to build profiles for Lou Gehrig's disease and other neuromuscular conditions.

Medidata stung by $4.8M wire transfer fraud

Medidata has promised to review its financial controls after fraudsters made away with $4.8 million. Midlevel employees in the eClinical company's finance department reportedly made the transfer to an overseas bank account after receiving a request for $4.8 million.

FDA's Mini-Sentinel set to graduate on October 1

The FDA's Mini-Sentinel has long since outgrown its "mini" moniker and is now ready to graduate from being a pilot project to being an integral part of the agency's drug-safety infrastructure. Many people welcome the program's progress, but doubts and dissenting voices remain.

MORE NEWS

From Our Sister Sites

FierceBiotech

Four months after it signed an option pact that included $33 million in an upfront and early milestone, along with $468 million in add-on incentives, Takeda has agreed to pay the freight on researching up to four more MacroGenics programs while adding up to $400 million each--$1.6 billion in total--in fresh milestones.

FierceBiotech

Chicago-based Baxter International has inked a 200,000-square-foot lease in the heart of Cambridge, MA's biotech hub which will become the new research center of its soon-to-be-spun-out biopharma division, Baxalta.